Global Platinum-based Anticancer Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Platinum-based Anticancer Drugs Market Research Report 2024
Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents used to treat cancer. They are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, popular drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development.
According to Mr Accuracy reports’s new survey, global Platinum-based Anticancer Drugs market is projected to reach US$ 1788.9 million in 2034, increasing from US$ 1541.9 million in 2022, with the CAGR of 2.1% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Platinum-based Anticancer Drugs market research.
The classification of platinum based cancer drug includes cisplatin, oxaliplatin, carboplatin and other types. The proportion of oxaliplatin is about 71%.
Platinum based cancer drug is widely used for colorectal cancer, ovarian cancer, lung cancer and other cancer. The most proportion of platinum based cancer drug is for colorectal cancer, and the proportion is about 62%.
Asia-Pacific is the largest market, with a sales market share nearly 53%. Following Asia-Pacific, Europe is the second largest sales place with the sales market share of 17%.
Market competition is intense. Sanofi, Hengrui Medicine, ASK Pharma, Yi Bai Pharmaceutical, Qilu Pharmaceutical and Teva, etc. are the leaders of the industry, with about 42% market shares.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Platinum-based Anticancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Sanofi-Aventis
Yakult honsha
Dr Reddy's laboratories
Sun Pharmaceutical
Teva
Fresenius Kabi
Hospira(Pfizer)
Mylan
Taj Pharmaceuticals
Jiangsu Hengrui Medicine
Nanjing Pharmaceutical Factory
Jiangsu Aosaikang Pharmaceutical
Qilu Pharmaceutical
Hisun Pharmaceutical
Luoxin
Lingnan Pharmacy
Hansoh Pharma
Segment by Type
Cisplatin
Carboplatin
Oxaliplatin
Nedaplatin
Others
Testicular Cancer
Osteosarcoma
Breast Cancer
Esophageal Cancer
NSCLC
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Platinum-based Anticancer Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Platinum-based Anticancer Drugs market is projected to reach US$ 1788.9 million in 2034, increasing from US$ 1541.9 million in 2022, with the CAGR of 2.1% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Platinum-based Anticancer Drugs market research.
The classification of platinum based cancer drug includes cisplatin, oxaliplatin, carboplatin and other types. The proportion of oxaliplatin is about 71%.
Platinum based cancer drug is widely used for colorectal cancer, ovarian cancer, lung cancer and other cancer. The most proportion of platinum based cancer drug is for colorectal cancer, and the proportion is about 62%.
Asia-Pacific is the largest market, with a sales market share nearly 53%. Following Asia-Pacific, Europe is the second largest sales place with the sales market share of 17%.
Market competition is intense. Sanofi, Hengrui Medicine, ASK Pharma, Yi Bai Pharmaceutical, Qilu Pharmaceutical and Teva, etc. are the leaders of the industry, with about 42% market shares.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Platinum-based Anticancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sanofi-Aventis
Yakult honsha
Dr Reddy's laboratories
Sun Pharmaceutical
Teva
Fresenius Kabi
Hospira(Pfizer)
Mylan
Taj Pharmaceuticals
Jiangsu Hengrui Medicine
Nanjing Pharmaceutical Factory
Jiangsu Aosaikang Pharmaceutical
Qilu Pharmaceutical
Hisun Pharmaceutical
Luoxin
Lingnan Pharmacy
Hansoh Pharma
Segment by Type
Cisplatin
Carboplatin
Oxaliplatin
Nedaplatin
Others
Segment by Application
Testicular Cancer
Osteosarcoma
Breast Cancer
Esophageal Cancer
NSCLC
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Platinum-based Anticancer Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices